Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-arterial chemotherapy plus total neoadjuvant therapy for organ preservation in distal rectal cancer
ChiCTR2300070620Phase 2Not yet recruiting
- Sponsor
- Affiliated Hospital of Youjiang Medical College for Nationalities
- Start
- May 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, raltitrexed, oxaliplatin and irinotecan in rectal adenocarcinoma and rectal cancer, sponsored by Affiliated Hospital of Youjiang Medical College for Nationalities. Primary endpoint: Complete response. Planned start May 2023; status: not yet recruiting.
02
Drugs
fluorouracilraltitrexedoxaliplatinirinotecan
03
Conditions
rectal adenocarcinomarectal cancer
Beyond the preview
Go deeper on ChiCTR2300070620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070620.